H0RSHOLM, Denmark--(BUSINESS WIRE)--Summary: LifeCycle Pharma initiates head-to-head clinical trial of LCP-Tacro versus Advagraf® and provides update on ongoing Phase II trials for LCP-Tacro in kidney and liver transplant recipients. LifeCycle Pharma A/S (OMX:LCP), an emerging specialty pharmaceutical company focused on developing and commercializing differentiated versions of existing drugs in large therapeutic areas such as cardiovascular disease, organ transplantation and immunosuppression, including recently Food and Drug Administration approved LCP-FenoChol, a fenofibrate for the treatment of hyperlipidemia and hypertriglyceridemia, today announced that it has initiated a Phase I clinical trial for its product candidate LCP-Tacro, a once-daily tacrolimus tablet used as an immunosuppressant in organ transplant recipients.
